← Back to Search

Education for Sickle Cell Trait (SCTaware Trial)

N/A

Waitlist Available

Led By Susan Creary, MD

Research Sponsored by Susan Creary

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 2 years

Awards & highlights

SCTaware Trial Summary

This trial will help researchers learn if a Sickle Cell Trait education program is feasible for parents with low health literacy.

SCTaware Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 2 years

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~2 years

This trial's timeline: 3 weeks for screening, Varies for treatment, and 2 years for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Feasibility of implementing of a Sickle Cell Trait education Program: The time required to train a sickle cell trait educator and to deliver the revised sickle cell trait education will be measured

Parental Sickle Cell Trait Knowledge

Secondary outcome measures

Decisional Conflict Scale

Parental Anxiety

Percentage of Parents who receive on-site Sickle Cell Trait testing

+1 more

SCTaware Trial Design

1Treatment groups

Experimental Treatment

Group I: EducationExperimental Treatment1 Intervention

During phase 1 of this study parents who attend in person education sessions will be recruited to have their standard sessions video-taped, timed, and reviewed by the SCTaware Team. Subjects will complete before and after education questionnaires that will then be reviewed to see how much participants learned about SCT, how education was not clear and/or appropriate (too much medical jargon). The SCTaware education will then be created based on review of these videos and participants' survey responses. For phase 2 of the study, the same recruitment strategy will be utilized. Participants will receive SCTaware and complete before and after questionnaires for evaluation. Participants in this phase will also complete follow-up questionnaires at 1 and 6 months.

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

Susan CrearyLead Sponsor

National Institutes of Health (NIH)NIH

2,698 Previous Clinical Trials

7,492,425 Total Patients Enrolled

National Heart, Lung, and Blood Institute (NHLBI)NIH

3,836 Previous Clinical Trials

47,850,783 Total Patients Enrolled

2 Trials studying Sickle Cell Trait

585 Patients Enrolled for Sickle Cell Trait

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the current enrollment capacity for this clinical research?

"That is correct. According to clinicaltrials.gov, this medical trial opened on June 18th 2019 and its information was recently updated on May 5th 2022. The study requires 135 participants from a single location."

Answered by AI

Are new participants being recruited for the research at this time?

"The information found on clinicaltrials.gov suggests this trial is currently recruiting participants, with the initial posting beginning June 18th 2019 and being updated as recently as May 5th 2022."

Answered by AI

What goals are the researchers attempting to accomplish with this experiment?

"This medical trial's primary evaluation metric over the course of 2 years is parental knowledge about Sickle cell Trait. Secondary metrics include perceptions of testing cost, on-site screening acceptance rate, and a reduction in parent anxiety regarding their child having the trait."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

A Program to Increase Sickle Cell Trait Knowledge Among Parent of Young Children Identified in Newborn Screening

Susan Creary 2019. "A Program to Increase Sickle Cell Trait Knowledge Among Parent of Young Children Identified in Newborn Screening". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT03984500.